Evaxion launches improved ai-immunology™ platform for vaccine antigen prediction

Copenhagen, denmark, sept. 19, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, launches an enhanced version of its clinically validated ai-immunology™ platform with an update of its eden™ ai prediction model. among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.
EVAX Ratings Summary
EVAX Quant Ranking